Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation

Oncogene

Volumn 29, Issue 41, 2010, Pages 5643-5650

  Tsang, Y H ^a,b   Lamb, A ^a   Romero Gallo, J ^c   Huang, B ^a   Ito, K ^d   Peek, R M ^c   Ito, Y ^b   Chen, L F ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

CagA; degradation; H. pylori; RUNX3; ubiquitination

Indexed keywords

CAGA PROTEIN; GENE PRODUCT; ONCOPROTEIN; PROTEASOME; TRANSCRIPTION FACTOR RUNX3;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETIC ASSOCIATION; HELICOBACTER PYLORI; INFECTION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MOTIF; STOMACH ADENOCARCINOMA; STOMACH CANCER; TRANSCRIPTION INITIATION; UBIQUITINATION;

AMINO ACID MOTIFS; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BINDING SITES; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; COS CELLS; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MICE; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; STOMACH NEOPLASMS; TRANSFECTION;

HELICOBACTER PYLORI;

EID: 77958016084     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.304     Document Type: Article

References (32)

1. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH et al. (1995). Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 55: 2111-2115.
2. Chang TL, Ito K, Ko TK, Liu Q, Salto-Tellez M, Yeoh KG et al. (2009). Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology 138: 255-265.
3. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL et al. (2005). RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation. Mol Cell Biol 25: 8097-8107.
4. Franco AT, Israel DA, Washington MK, Krishna U, Fox JG, Rogers AB et al. (2005). Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci USA 102: 10646-10651.
5. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH et al. (1999). Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem 274: 31577-31582.
6. Hatakeyama M. (2004). Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 4: 688-694. (Pubitemid 39215067)
7. Hatakeyama M. (2008). SagA of CagA in Helicobacter pylori pathogenesis. Curr Opin Microbiol 11: 30-37.
8. Hatakeyama M. (2009). Helicobacter pylori and gastric carcinogenesis. J Gastroenterol 44: 239-248.
9. Higashi H, Tsutsumi R, Fujita A, Yamazaki S, Asaka M, Azuma T et al. (2002a). Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phospho-rylation sites. Proc Natl Acad Sci USA 99: 14428-14433.
10. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M et al. (2002b). SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 295: 683-686.
11. Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC, Lu PJ et al. (2009). Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol 16: 1686-1694.
12. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. (2003). Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 125: 1636-1644.
13. Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS et al. (2008). RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14: 226-237.
14. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H et al. (2005). RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750.
15. Ito Y. (2004). Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 23: 4198-4208.
16. Katayama Y, Takahashi M, Kuwayama H. (2009). Helicobacter pylori causes runx3 gene methylation and its loss of expression in gastric epithelial cells, which is mediated by nitric oxide produced by macrophages. Biochem Biophys Res Commun 388: 496-500.
17. Kitajima Y, Ohtaka K, Mitsuno M, Tanaka M, Sato S, Nakafusa Y et al. (2008). Helicobacter pylori infection is an independent risk factor for Runx3 methylation in gastric cancer. Oncol Rep 19: 197-202.
18. Lamb A, Yang XD, Tsang YH, Li JD, Higashi H, Hatakeyama M et al. (2009). Helicobacter pylori CagA activates NF-kappaB by targeting TAK1 for TRAF6-mediated Lys 63 ubiquitination. EMBO Rep 10: 1242-1249.
19. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ et al. (2002). Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124.
20. Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H et al. (2007). Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene 26: 4617-4626.
21. Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A et al. (2008). Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci USA 105: 1003-1008.
22. Parsonnet J, Friedman GD, Orentreich N, Vogelman H. (1997). Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut 40: 297-301.
23. Peek Jr. RM. (2005). Orchestration of aberrant epithelial signaling by Helicobacter pylori CagA. Sci STKE 2005: pe14.
24. Peek Jr. RM, Blaser MJ. (2002). Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2: 28-37.
25. Peng Z, Wei D, Wang L, Tang H, Zhang J, Le X et al. (2006). RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer. Clin Cancer Res 12: 6386-6394.
26. Pickart CM. (2001). Mechanisms underlying ubiquitination. Annu Rev Biochem 70: 503-533.
27. Polk DB, Peek Jr. RM. (2010). Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 10: 403-414.
28. Sudol M, Chen HI, Bougeret C, Einbond A, Bork P. (1995). Characterization of a novel protein-binding module-the WW domain. FEBS Lett 369: 67-71.
29. Sugiura H, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Mori Y et al. (2008). Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep 19: 713-719.
30. Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang L et al. (2005). Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 65: 4809-4816.
31. Yamamura Y, Lee WL, Inoue K, Ida H, Ito Y. (2006). RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 281: 5267-5276.
32. Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K et al. (2006). The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apopto-sis. Mol Cell Biol 26: 4474-4488.